← Back to Clinical Trials
Recruiting NCT06869590

NCT06869590 Identification of Anti-HIF 1alpha Autoantibodies in Patients With Anorexia Nervosa and Characterization of Their Pathogenic Potential in Undernutrition-associated Hepatic Cytolysis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06869590
Status Recruiting
Phase
Sponsor Assistance Publique Hopitaux De Marseille
Condition Hepatic Cytolysis
Study Type INTERVENTIONAL
Enrollment 250 participants
Start Date 2026-02-02
Primary Completion 2027-05-24

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
blood samplingblood sampling after 3-4 months

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 250 participants in total. It began in 2026-02-02 with a primary completion date of 2027-05-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Anorexia nervosa (AN) is a psychiatric disorder belonging to the eating disorders (EDs). It is internationally recognized as a priority for improving health care. Among the markers of severity of undernutrition is hepatic cytolysis. Around 30-50% of patients with AN present with hepatic cytolysis, of variable intensity, and usually associated with severe undernutrition. In a previous study, we demonstrated the presence of autoantibodies against HIF1alpha (Hypoxic inducible Factor 1 alpha) in 22% of cases in a sample of patients with AN. HIF1alpha (HIF1a) is a major transcription factor involved in the regulation of satiety and hunger. These autoantibodies were positive in 80% of AN patients with hepatic cytolysis. Taken together, these data led us to hypothesize an anti-HIF1a autoimmune mechanism in AN, potentially involved in the patients' hepatic cytolysis. This pioneering study, demonstrating the existence of anti-HIF1a autoantibodies, was carried out on a population of 18 patients with AN. To extend investigator's hypothesis, these results need to be confirmed on a larger number of patients, thus increasing the number of patients with AN and hepatic cytolysis. To determine the relevance of these autoantibodies in AN, "healthy" subjects and patients without AN but with hepatic cytolysis should be tested in parallel. Finally, the in vitro pathogenic potential of autoantibodies can be confirmed on a larger scale and studied in greater detail. The main aim of our study is to evaluate the association between the presence of anti-HIF1a autoantibodies (AAHIF) and that of hepatic cytolysis in patients with anorexia nervosa and undernutrition. This study is a prospective, cross-sectional, descriptive, multicenter, 2-arm study. 250 patients will be included. Experimental group (n=100) * Patients with anorexia nervosa and undernutrition with hepatic cytolysis (CH) (n=70) * Patients with anorexia nervosa and undernutrition without hepatic cytolysis (n=30) Comparator control groups (n=150) * Control patients under 18 years of age, treated at the CHU de la Timone for scheduled non-inflammatory surgery (orthopedic, ENT, etc.) (n=50): Minor patients * Patients (children and adults) with hepatic cytolysis without anorexia nervosa (n=50): Patients without AN with CH * Samples from French blood donation establishment: control group consisting of biological blood samples from healthy individuals from the Etablissement Français du Sang (n=50)

Eligibility Criteria

Inclusion Criteria: Experimental group: * Male or female, 6 to 65 years of age * Anorexia nervosa diagnosed according to DSM-5 criteria * Presence of undernutrition according to HAS 2019 criteria * Patient having received information about the study and having signed an informed consent form * Beneficiary or beneficiary of a social security scheme Control group: * Minor patients : * Male or female strictly under 18 years of age * Patients undergoing scheduled non-inflammatory surgery (orthopedic, ENT, etc.) * Patients who have been informed about the study and have signed an informed consent form. * Patients who are beneficiaries or entitled beneficiaries of a social security scheme. * Patients without anorexia with livers cytolysis : * Male or female between 18 and 65 years of age * With hepatic cytolysis determined by an ALT value at least equal to twice the normal value * Patient having received information about the study and having signed an informed consent form * Patient who is a beneficiary or eligible beneficiary of a social security scheme. * samples Etablissement Français de don de sang: no specific criteria Exclusion Criteria: * Patient in a period of exclusion from another research protocol at the time consent is signed. * Opposition of patient and parents or legal guardians * Psychiatric disorder preventing patient consent to study * Person unable to understand the French language * Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women).

Contact & Investigator

Central Contact

Nathalie Bardin, Pr

✉ promotion.interne@ap-hm.fr

📞 0491435817

Frequently Asked Questions

Who can join the NCT06869590 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 65 Years, studying Hepatic Cytolysis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06869590 currently recruiting?

Yes, NCT06869590 is actively recruiting participants. Contact the research team at promotion.interne@ap-hm.fr for enrollment information.

Where is the NCT06869590 trial being conducted?

This trial is being conducted at Marseille, France.

Who is sponsoring the NCT06869590 clinical trial?

NCT06869590 is sponsored by Assistance Publique Hopitaux De Marseille. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology